共 194 条
[1]
Serugal B(2015)Failures in phase III: causes and consequences Clin Cancer Res 21 4552-4560
[2]
Ocana A(2017)Colorectal cancer–global burden, trends, and geographical variations J Surg Oncol 115 619-630
[3]
Amir E(2014)PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer J Clin Oncol 32 2240-2247
[4]
Douaiher J(2016)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial Lancet Oncol 17 1426-1434
[5]
Ravipati A(2019)A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology Eur J Cancer 106 196-211
[6]
Chowdhury S(2013)Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab J Clin Oncol 31 3764-3775
[7]
Schwartzberg LS(2015)Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest Ann Oncol 26 1188-1194
[8]
Rivera F(2015)Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer Eur J Cancer 51 1231-1242
[9]
Karthaus M(2016)Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX Plus Cetuximab (JACCRO CC-05) Targ Oncol 11 799-806
[10]
Stintzing S(2015)Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis Eur J Cancer 51 800-807